JP2016519933A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519933A5 JP2016519933A5 JP2016513129A JP2016513129A JP2016519933A5 JP 2016519933 A5 JP2016519933 A5 JP 2016519933A5 JP 2016513129 A JP2016513129 A JP 2016513129A JP 2016513129 A JP2016513129 A JP 2016513129A JP 2016519933 A5 JP2016519933 A5 JP 2016519933A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically engineered
- blood cell
- enucleated blood
- engineered enucleated
- erythrocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000601 blood cell Anatomy 0.000 claims 19
- 210000003743 erythrocyte Anatomy 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 108091005703 transmembrane proteins Proteins 0.000 claims 7
- 102000035160 transmembrane proteins Human genes 0.000 claims 7
- 108010052285 Membrane Proteins Proteins 0.000 claims 6
- 102000018697 Membrane Proteins Human genes 0.000 claims 6
- 210000003617 erythrocyte membrane Anatomy 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102100035716 Glycophorin-A Human genes 0.000 claims 2
- 108091005250 Glycophorins Proteins 0.000 claims 2
- 108091005956 Type II transmembrane proteins Proteins 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019182854A JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822071P | 2013-05-10 | 2013-05-10 | |
| US61/822,071 | 2013-05-10 | ||
| PCT/US2014/037554 WO2014183071A2 (en) | 2013-05-10 | 2014-05-09 | In vitro production of red blood cells with sortaggable proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182854A Division JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519933A JP2016519933A (ja) | 2016-07-11 |
| JP2016519933A5 true JP2016519933A5 (enExample) | 2017-06-22 |
| JP6599848B2 JP6599848B2 (ja) | 2019-10-30 |
Family
ID=51867887
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513129A Expired - Fee Related JP6599848B2 (ja) | 2013-05-10 | 2014-05-09 | ソルタギング可能なタンパク質を有する赤血球のｉｎｖｉｔｒｏ生成 |
| JP2019182854A Expired - Fee Related JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
| JP2021163272A Pending JP2022001063A (ja) | 2013-05-10 | 2021-10-04 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182854A Expired - Fee Related JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
| JP2021163272A Pending JP2022001063A (ja) | 2013-05-10 | 2021-10-04 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10471099B2 (enExample) |
| EP (4) | EP3546484B1 (enExample) |
| JP (3) | JP6599848B2 (enExample) |
| AU (2) | AU2014262474B2 (enExample) |
| ES (1) | ES2901383T3 (enExample) |
| HK (1) | HK1222662A1 (enExample) |
| WO (1) | WO2014183071A2 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10081684B2 (en) | 2011-06-28 | 2018-09-25 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| EP2994530A4 (en) | 2013-05-10 | 2016-11-16 | Whitehead Biomedical Inst | PROTEIN MODIFYING LIVING CELLS USING SORTASE |
| HK1222662A1 (zh) | 2013-05-10 | 2017-07-07 | Whitehead Institute For Biomedical Research | 体外生产具有可分选蛋白的无核红细胞 |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| CN106459995B (zh) | 2013-11-07 | 2020-02-21 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| WO2015073746A2 (en) | 2013-11-13 | 2015-05-21 | Whitehead Institute For Biomedical Research | 18f labeling of proteins using sortases |
| EP3071515A2 (en) | 2013-11-18 | 2016-09-28 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| EP3583946A1 (en) | 2014-04-01 | 2019-12-25 | Rubius Therapeutics, Inc. | Enucleated hematopoietic cells comprising an exogenous antigen |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US10053683B2 (en) | 2014-10-03 | 2018-08-21 | Whitehead Institute For Biomedical Research | Intercellular labeling of ligand-receptor interactions |
| EP3233906B1 (en) | 2014-12-17 | 2019-05-01 | F.Hoffmann-La Roche Ag | Enzymatic one-pot reaction for double polypeptide conjugation in a single step using sortase |
| JP6800154B2 (ja) | 2014-12-17 | 2020-12-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 結合形成酵素の活性アッセイ |
| WO2016183482A1 (en) * | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| EP3353314A1 (en) | 2015-09-25 | 2018-08-01 | H. Hoffnabb-La Roche Ag | Transamidation employing sortase a in deep eutectic solvents |
| JP6895953B2 (ja) | 2015-09-25 | 2021-06-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ソルターゼａを利用してチオエステルを作製するための方法 |
| US12048753B2 (en) | 2015-10-01 | 2024-07-30 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
| SG10202104041PA (en) | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
| PT3402491T (pt) | 2016-01-11 | 2022-03-03 | Rubius Therapeutics Inc | Composições e métodos relacionados com sistemas celulares terapêuticos multimodais para indicações de cancro |
| CN108778318B (zh) | 2016-01-14 | 2022-05-03 | 北卡罗莱纳州立大学 | 葡萄糖响应性胰岛素递送组合物和方法 |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| EP3548050A1 (en) | 2016-12-02 | 2019-10-09 | Rubius Therapeutics, Inc. | Compositions and methods related to cell systems for penetrating solid tumors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| CA3052142A1 (en) | 2017-02-17 | 2018-08-23 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| WO2019017940A1 (en) | 2017-07-19 | 2019-01-24 | Rubius Therapeutics, Inc. | COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIMODAL THERAPEUTIC CELLULAR SYSTEMS FOR THE TREATMENT OF INFECTIOUS DISEASE |
| WO2019017937A1 (en) | 2017-07-19 | 2019-01-24 | Rubius Therapeutics, Inc. | COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIMODAL THERAPEUTIC CELLULAR SYSTEMS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASE |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| US10960071B2 (en) * | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| EP4328314A3 (en) | 2017-08-22 | 2024-03-20 | Tessera Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
| US20200206269A1 (en) * | 2017-08-23 | 2020-07-02 | Whitehead Institute For Biomedical Research | Production of enucleated red blood cells and uses thereof |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3703751A2 (en) | 2017-11-03 | 2020-09-09 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| CN111712254A (zh) * | 2017-12-23 | 2020-09-25 | 鲁比厄斯治疗法股份有限公司 | 人工抗原呈递细胞和使用方法 |
| WO2019133881A1 (en) | 2017-12-29 | 2019-07-04 | Rubius Therapeutics, Inc. | Gene editing and targeted transcriptional modulation for enginerering erythroid cells |
| US20190330591A1 (en) | 2018-01-10 | 2019-10-31 | Rubius Therapeutics, Inc. | Amplifiable rnas for therapeutic cell systems |
| MX2020009359A (es) | 2018-03-08 | 2021-01-29 | Rubius Therapeutics Inc | Sistemas de celulas terapeuticas y metodos para el tratamiento de cancer y enfermedades infecciosas. |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| SG11202102688PA (en) * | 2018-09-21 | 2021-04-29 | Univ City Hong Kong | Surface modified extracellular vesicles |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| EP3891269A1 (en) * | 2018-12-03 | 2021-10-13 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CA3130750A1 (en) * | 2019-02-20 | 2020-08-27 | Rubius Therapeutics, Inc. | Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use |
| EP3942043A2 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| KR20220005028A (ko) | 2019-04-26 | 2022-01-12 | 루비우스 테라퓨틱스, 아이엔씨. | 탈핵 적혈구를 포함하는 조성물 |
| US20200370016A1 (en) | 2019-05-24 | 2020-11-26 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| JP2023500327A (ja) | 2019-11-04 | 2023-01-05 | ルビウス セラピューティクス， インコーポレイテッド | ミオイノシトールを使用して除核赤芽球細胞を生成する方法 |
| KR20220093196A (ko) | 2019-11-04 | 2022-07-05 | 루비우스 테라퓨틱스, 아이엔씨. | 타우린 또는 하이포타우린을 사용하여 제핵 적혈구 세포를 생성하는 방법 |
| US11970718B2 (en) | 2020-01-13 | 2024-04-30 | Carmine Therapeutics Pte. Ltd. | Nucleic acid loaded extracellular vesicles |
| AU2021217399A1 (en) * | 2020-02-07 | 2022-08-25 | The Regents Of The University Of California | Methods and use for bioengineering enucleated cells |
| CN115151636A (zh) | 2020-02-10 | 2022-10-04 | 鲁比厄斯治疗法股份有限公司 | 包含hla-g多肽的经工程改造的红系细胞及其使用方法 |
| CN115335064B (zh) * | 2020-03-20 | 2024-08-30 | 西湖生物医药科技(杭州)有限公司 | 修饰的红细胞及其用于递送药剂的用途 |
| BR112022022603A2 (pt) | 2020-05-08 | 2023-01-17 | Broad Inst Inc | Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla |
| EP4149440A1 (en) | 2020-05-11 | 2023-03-22 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
| CN116547000A (zh) * | 2020-10-30 | 2023-08-04 | 西湖生物医药科技(杭州)有限公司 | 经修饰的红细胞及其在递送活性剂中的用途 |
| EP4243839A1 (en) | 2020-11-13 | 2023-09-20 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| TW202241470A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 治療人類個體腫瘤之方法 |
| TW202241471A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 提高個體中NKp30陽性淋巴球的方法及其用途 |
| US20240110153A1 (en) * | 2021-01-29 | 2024-04-04 | National University Of Singapore | Surface Modified Red Blood Cells And Methods Of Generating The Same |
| CN116888258A (zh) * | 2021-02-04 | 2023-10-13 | 西湖生物医药科技(杭州)有限公司 | 修饰的红细胞及其治疗高尿酸血症和痛风的用途 |
| TW202304482A (zh) | 2021-03-14 | 2023-02-01 | 美商盧比亞斯治療公司 | 於個體中增加nkg2d陽性淋巴球之方法及其用途 |
| EP4312997A1 (en) | 2021-03-31 | 2024-02-07 | Carmine Therapeutics Pte. Ltd. | Extracellular vesicles loaded with at least two different nucleic acids |
| TW202317179A (zh) | 2021-06-03 | 2023-05-01 | 美商盧比亞斯治療公司 | 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法 |
| WO2023284742A1 (en) * | 2021-07-13 | 2023-01-19 | Westlake Therapeutics (Hangzhou) Co. Limited | Cells modified by conjugated n-terminal glycine and uses thereof |
| CN120152732A (zh) * | 2022-10-24 | 2025-06-13 | 西湖生物医药科技(上海)有限公司 | 诱导特异性免疫耐受的组合 |
| JP2026514096A (ja) * | 2023-04-12 | 2026-05-01 | サイトナス セラピューティクス インコーポレイテッド | 治療用細胞の製造 |
| EP4735584A1 (en) * | 2023-06-30 | 2026-05-06 | The Children's Hospital of Philadelphia | Click chemistry assisted cell surface engineering for restoring lentivirus entry |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5670132A (en) | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| US5728369A (en) | 1994-10-05 | 1998-03-17 | Immunomedics, Inc. | Radioactive phosphorus labeling of proteins for targeted radiotherapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| CA2238434A1 (en) | 1995-12-15 | 1997-06-19 | Systemix, Inc. | Method for obtaining retroviral vector supernatant having high transduction efficiency |
| CA2365523A1 (en) | 1999-04-15 | 2000-10-26 | The Regents Of The University Of California | Identification of sortase gene |
| CA2413538A1 (en) | 2000-07-06 | 2002-01-17 | Bristol-Myers Squibb Pharma Company | Stable radiopharmaceutical compositions and methods for preparation thereof |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US6960473B2 (en) * | 2003-02-27 | 2005-11-01 | Istituto Superiore Di Sanita | In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients |
| WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
| WO2005086654A2 (en) | 2004-02-27 | 2005-09-22 | The Trustees Of Princeton University | Self-cleaving affinity tags and methods of use |
| JP5139799B2 (ja) * | 2004-06-04 | 2013-02-06 | ユニベルシテ ピエール エ マリー キュリー（パリ シズエム） | 赤血球細胞の生産方法 |
| US8398956B2 (en) | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| US20120034155A1 (en) | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
| US8211656B2 (en) | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| US20100092470A1 (en) | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| JP2010115136A (ja) * | 2008-11-12 | 2010-05-27 | Teruyuki Nagamune | Ｎ末端標識膜蛋白質の作製方法、及びｎ末端標識膜蛋白質を表層に有する細胞 |
| WO2010078376A2 (en) | 2008-12-30 | 2010-07-08 | Ventana Medical Systems, Inc. | Fc-specific polymer-conjugated antibodies and their diagnostic use |
| WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US9173961B2 (en) | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| DK2539441T3 (en) * | 2010-02-22 | 2017-01-09 | Univ Pierre Et Marie Curie Paris 6 | Cell culture medium for the growth and differentiation of cells of hematopoietic lineage |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| WO2011133704A2 (en) | 2010-04-20 | 2011-10-27 | Whitehead Institute For Biomedical Researh | Modified polypeptides and proteins and uses thereof |
| WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| US10081684B2 (en) * | 2011-06-28 | 2018-09-25 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
| CN102559600A (zh) | 2011-12-29 | 2012-07-11 | 上海交通大学医学院 | 一种人工抗原递呈细胞及其在nk细胞扩增中的应用 |
| CN104159911A (zh) | 2012-03-07 | 2014-11-19 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的模拟肽化合物 |
| EP2836507A4 (en) | 2012-04-13 | 2016-08-24 | Whitehead Biomedical Inst | SORTAS-MODIFIED VHH DOMAINS AND USES THEREOF |
| US20140030697A1 (en) | 2012-06-14 | 2014-01-30 | Massachusetts Institute Of Technology | Sortase-mediated modification of viral surface proteins |
| US9267127B2 (en) | 2012-06-21 | 2016-02-23 | President And Fellows Of Harvard College | Evolution of bond-forming enzymes |
| US9511350B2 (en) | 2013-05-10 | 2016-12-06 | Clean Diesel Technologies, Inc. (Cdti) | ZPGM Diesel Oxidation Catalysts and methods of making and using same |
| EP2994530A4 (en) | 2013-05-10 | 2016-11-16 | Whitehead Biomedical Inst | PROTEIN MODIFYING LIVING CELLS USING SORTASE |
| HK1222662A1 (zh) | 2013-05-10 | 2017-07-07 | Whitehead Institute For Biomedical Research | 体外生产具有可分选蛋白的无核红细胞 |
| CN111876387A (zh) | 2013-05-15 | 2020-11-03 | 罗切斯特大学 | 人广泛自我更新型成红细胞(esre) |
| WO2015051188A1 (en) | 2013-10-02 | 2015-04-09 | Washington University | Heterocyclic molecules for biomedical imaging and therapeutic applications |
| WO2015057863A1 (en) | 2013-10-15 | 2015-04-23 | Regents Of The University Of Minnesota | Triorthogonal reagents for dual protein conjugation |
| WO2015073746A2 (en) | 2013-11-13 | 2015-05-21 | Whitehead Institute For Biomedical Research | 18f labeling of proteins using sortases |
| US10053683B2 (en) | 2014-10-03 | 2018-08-21 | Whitehead Institute For Biomedical Research | Intercellular labeling of ligand-receptor interactions |
| WO2016183482A1 (en) | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| US12048753B2 (en) | 2015-10-01 | 2024-07-30 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
| US20200206269A1 (en) | 2017-08-23 | 2020-07-02 | Whitehead Institute For Biomedical Research | Production of enucleated red blood cells and uses thereof |
| US20200370016A1 (en) * | 2019-05-24 | 2020-11-26 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells |
-
2014
- 2014-05-09 HK HK16110752.9A patent/HK1222662A1/zh unknown
- 2014-05-09 EP EP19171188.6A patent/EP3546484B1/en not_active Not-in-force
- 2014-05-09 ES ES19171188T patent/ES2901383T3/es active Active
- 2014-05-09 EP EP19219550.1A patent/EP3693398A1/en not_active Withdrawn
- 2014-05-09 JP JP2016513129A patent/JP6599848B2/ja not_active Expired - Fee Related
- 2014-05-09 EP EP19171190.2A patent/EP3546485A1/en not_active Withdrawn
- 2014-05-09 WO PCT/US2014/037554 patent/WO2014183071A2/en not_active Ceased
- 2014-05-09 EP EP14795167.7A patent/EP2994491A4/en not_active Withdrawn
- 2014-05-09 AU AU2014262474A patent/AU2014262474B2/en not_active Ceased
- 2014-05-09 US US14/890,241 patent/US10471099B2/en active Active - Reinstated
-
2018
- 2018-03-23 US US15/934,177 patent/US11266695B2/en active Active
-
2019
- 2019-09-16 US US16/572,425 patent/US11992505B2/en active Active
- 2019-10-03 JP JP2019182854A patent/JP6960177B2/ja not_active Expired - Fee Related
- 2019-12-16 AU AU2019283766A patent/AU2019283766B2/en not_active Ceased
-
2021
- 2021-10-04 JP JP2021163272A patent/JP2022001063A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | High-mobility group box-1 and its role in angiogenesis | |
| WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| EP4289484A3 (en) | Anti-ctla-4 antibodies and methods of use thereof | |
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| SA517380842B1 (ar) | بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام | |
| JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| JP2019527055A5 (enExample) | ||
| GB2496794A (en) | Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract | |
| JP2012126742A5 (enExample) | ||
| MX2020006822A (es) | Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa. | |
| MX2019001136A (es) | Partículas similares a virus con recubrimiento de alta densidad para inducir la expresión de anticuerpos. | |
| EA201591213A1 (ru) | Вакцины против вируса гепатита b | |
| AR056245A1 (es) | Membranas virales reconstituidas funcionales que contienen un coadyuvante | |
| WO2015140172A3 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| EA201891639A1 (ru) | Аминокислотные и пептидные конъюгаты и способ конъюгации | |
| WO2015095167A3 (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| MY184576A (en) | Recombinant proteins and their therapeutic uses | |
| MX387764B (es) | Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. | |
| JP2016508143A5 (enExample) | ||
| JP2018023397A5 (enExample) | ||
| EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
| WO2014144621A3 (en) | Modified fc fusion proteins | |
| RU2019113989A (ru) | Лекарственное средство | |
| WO2018175740A8 (en) | Anti-tmeff1 antibodies and antibody drug conjugates |